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Abstract:  Over  the  last  decade,  decreasing  effectiveness  of  conventional 
antimicrobial-drugs  has  caused  serious  problems  due  to  the  rapid  emergence  of 
multidrug-resistant pathogens. Furthermore, biofilms, which are microbial communities that 
cause  serious  chronic  infections  and  dental  plaque,  form  environments  that  enhance 
antimicrobial resistance. As a result, there is a continuous search to overcome or control 
such  problems,  which  has  resulted  in  antimicrobial  peptides  being  considered  as  an 
alternative to conventional drugs. Antimicrobial peptides are ancient host defense effector 
molecules in living organisms. These peptides have been identified in diverse organisms and 
synthetically developed by using peptidomimic techniques. This review was conducted to 
demonstrate the mode of action by which antimicrobial peptides combat multidrug-resistant 
bacteria and prevent biofilm formation and to introduce clinical uses of these compounds for 
chronic disease, medical devices, and oral health. In addition, combinations of antimicrobial 
peptides and conventional drugs were considered due to their synergetic effects and low cost 
for therapeutic treatment. 
Keywords:  mode  of  action;  lipopolysaccharide;  quorum  sensing;  dental  plaque;  
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1. Introduction 
Since penicillin was first discovered by Fleming in 1928, a large number of antibiotics have been 
identified, developed and clinically used in antimicrobial pharmatherapeutics. However, the widespread 
use of antibiotics was soon followed by the emergence of multidrug-resistant (MDR) microbes due to 
various reasons including abuse and the increasing use of antibiotics in the biomedical and agricultural 
fields. In addition to bacterial evolution, a number of patients in hospitals worldwide are currently 
suffering  from  superbugs  such  as  vancomycin  resistant  enterococci  (VRE),  methicillin  resistant 
Staphylococcus  aureus  (MRSA)  and  MDR  bacteria.  Indeed,  from  1999  to  2005,  the  number  of 
hospitalizations associated with MRSA infections increased by 119%, or ~14% per year [1]. In addition, 
the  Center  for  Disease  Control  and  Prevention  (CDC)  reported  that  1.7  million  people  were 
nosocomially infected in hospitals in 2002 and 99,000 deaths were occurring annually in the United 
States due to drug-resistant microbes [2]. Moreover, as of early 2005 the number of deaths in the United 
Kingdom attributed to MRSA was estimated to be 3,000 per year [3]. 
Biofilms are sessile microbial communities of microbes that are adhered to various surfaces and 
encaged in a self-produced extracellular matrix, and have given rise to another problem in clinical 
therapeutics [4]. Specifically,  bacterial cells growing  in a biofilm are physiologically distinct from 
planktonic cells of the same bacteria and are embedded within a self-produced matrix of extracelluar 
polymeric  substance  (EPS)  [4,5],  which  can  increase  antibiotic  resistance  by  up  to  1000  fold  [6]. 
Infectious processes in biofilms are related to various routes such as urinary tract [7] and catheter 
infections  [8]  and  the  formation  of  dental  plaque  [9].  Among  those,  a  total  of  250,000  cases  of 
catheter-associated blood stream infections that occur annually in the USA are attributed to a mortality 
rate of 12%~25% for each infection, with a treatment cost of $25,000 per episode [10]. 
Currently,  many studies are being conducted to address the above problems,  multidrug-resistant 
bacteria and biofilm formation. The results of these studies have led to antimicrobial peptides being 
considered as an alternative drug for conventional antibiotics. They have weak antimicrobial activity but 
potent and broad immune modulatory activity when the host organism is invaded by pathogenic microbes 
or viruses. Indeed many use the generic term “host defense” peptides [11–13]. They do not activate adaptive 
immunity,  but  rather  increase  the  efficiency  thereof  through  adjuvant  activity.  Since  antimicrobial 
peptides  were  initially  identified  in  frogs  and  insects  in  the  1980s  (for  example,  cecropins  [14],  
PGLa [15],  magainins [16]), many additional peptides  have  been  found and over 1200 have  been 
isolated  to  date  (http://aps.unmc.edu/AP/main.php  and  http://www.bbcm.units.it/~tossi/amsdb.html). 
Although the sequences and structures of these peptides are highly diverse, they have some common 
properties, including amphipathic secondary structures within membranes, a positive net charge under 
physiological conditions, small size, rapid binding to biological membranes, and usually the ability to 
kill invading microorganisms within minutes [17,18]. 
The mode of action of antibiotic peptides is not fully understood, but it is believed that their major 
targets are cytoplasmic membrane and intracellular molecules [19,20]. It is also believed that it is very 
difficult for bacteria to develop resistance to antimicrobial peptides because most kill bacterial cells 
quickly  through  their  actions  on  the  entire  cytoplasmic  membrane  or  can  act  through  complex 
mechanism  [12].  Although  resistance  for  antimicrobial  peptide  has  been  reported,  acquirement  of 
resistance by changing the charge on surface molecules [21,22] or proteolytic cleavage by the release of Int. J. Mol. Sci. 2011, 12                    
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extracelluar protease [23,24], is limited and also takes long periods when compared to conventional 
drugs. Although antimicrobial peptides are much more expensive than antibiotics, many studies have 
found that antimicrobial peptides act effectively  in synergy with currently used antibiotics  against 
multidrug-resistant bacteria [25–27] because they function through different mechanisms. 
In this review, we will focus on the mode of action of antibiotics and antimicrobial peptides, their 
current use against multidrug-resistant bacteria, and recent findings regarding their use in the prevention 
of biofilms. 
2. Use of AMPs in Preventing Multidrug-Resistant Bacteria 
Major targets of antimicrobial peptides in bacterial cells can be divided into two cellular sites, the cell 
wall  containing  outer  membrane  and  inner  membrane  and  cytoplasm.  Although  the  mechanisms 
inducing antibiotic-resistance are also diverse, the cellular action of antimicrobial peptides is separated 
from these mechanisms. For that reason, antimicrobial peptides have the potential for use in a unique 
antibiotic drug for combating or preventing the formation of multidrug-resistant bacteria. 
2.1. Modes of Antibacterial Action 
2.1.1. Lipopolysaccharide (LPS) Neutralization or Disaggregation by Antimicrobial Peptides 
LPSs are major components of the outer leaflet of the outer membrane in Gram-negative bacteria. 
LPSs  consist  of  an  O-specific  chain  that  is  highly  variable  in  different  bacterial  strains,  a  core 
oligosaccharide, and lipid A [28]. LPSs are essential for bacterial growth and viability, but macrophages 
stimulated by LPS induce the release of pro-inflammatory cytokines (TNF-α, IL1 and IL6) into the 
blood, resulting in septic shock [29–31]. Accordingly, LPSs are an excellent target for antimicrobial 
peptides  because  they  have  the  potential  to  both  directly  inhibit  the  growth of  multidrug-resistant 
bacteria and to neutralize the action of released LPS due to its stimulation of immune cells. 
Antimicrobial peptides generally bind to LPS through electrostatic interactions between their cationic 
amino acids (Lysine and Arginine) and head groups of LPS, and this complex is stabilized through 
hydrophobic interactions between the hydrophobic amino acids of the peptide and fatty acyl chains of 
LPS  [32,33].  Since  polymyxins,  which  are  pentabasic  decapeptide  antibiotics,  were  discovered  in 
Bacillus polymyxa [34], only two have been produced commercially, polymyxin B and E (colistin) [35]. 
Their action, which occurs via binding to lipid A of LPS and permeabilization of the outer membrane,  
is  restricted  to  Gram-negative  bacteria  [36].  Sushi  peptides,  which  are  derived  from  Factor  C 
(LPS-sensitive  serine protease of the  horseshoe  crab coagulation cascade), disrupt LPS aggregates 
through detergent-like action and also have LPS-neutralizing activity [32,37]. Moreover, even though 
PMAP-23, which is a porcine myeloid antibacterial peptide composed of 23 residues that adopts a 
helix-hinge-helix structure in  membrane-mimetic environments, showed a killing activity against a 
broad spectrum of microbial organisms, carboxyl terminus led to growth inhibition of E. coli via the 
interaction with outer membrane containing LPS [38]. Conversely, several AMPs prevent LPS-induced 
cytokine induction in macrophages, resulting in interruption of the development of septic shock in 
animal models [39–41]. Int. J. Mol. Sci. 2011, 12                    
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Recently, the emergence of some bacteria with modifications of lipid A and LPS, such as lipid A 
acylation [42], aminoarabinose of lipid A [43], and myristylation of LPS [44] which are induced by 
PhoP/PhoQ and PmeAB regulatory systems, has resulted in antimicrobial peptides having reduced 
antibacterial activity. However, this antimicrobial peptide-mediated resistance occurs when bacteria 
surviving in the presence of antimicrobial peptide are conducted by repeated treatments during a very 
long-term. Moreover, the net negative surface charge decreased by these modifications reduces the 
electrostatic  interaction  with  positively  charged  antimicrobial  peptides.  Within  the  limits  of  this 
interaction, it is expected that this process may be overcome if other antimicrobial peptides which do not 
interact with LPS or possess other modes of action in bacteria were substituted. 
2.2. Cell Wall-Lipid II 
Cell walls of Gram-positive bacteria are formed by peptidoglycan, which are composed of polymers 
of sugars and amino acids outside the plasma membrane [45]. Occasionally, inhibition of the production 
of  peptidoglycan  leads  to  resistance  against  antibiotics  such  as  penicillin,  which  is  inhibited  via 
penicillin-binding proteins or transpeptidases [46,47]. MRSA is also related to the existence of the 
penicillin-binding protein 2a (PBP2a), which is not present in susceptible S. aureus [48,49]. Vancomycin 
resistance is caused by the production of depsipeptide D-Ala-D-Ala in the peptidoglycan [50]. Although 
a number of antimicrobial peptides have been shown to be active against MRSA and VRE, in this section, 
we focus on antibacterial peptides with unusual amino acids, which are known as lantibiotics, because 
many of them exert antibacterial action through the interaction with cell wall components.  
Lantibiotics are ribosomally-synthesized and post-translationally modified peptides that contain an 
intramolecular ring structure.  These compounds  are produced by Gram-positive  bacteria and exert 
potent inhibitory action against a wide-spectrum of bacteria [51]. These compounds are classified as 
either type-A or type-B, and damage the bacterial membrane and inhibit the production of enzymes, 
respectively [51]. Type-A lantibiotics include nisin [52], subtilin [53], epidermin [54], and Pep5 [55], 
while type-B include mersacidin [56] and cinnamycin [57]. The most well-known lantibiotic is nisin, 
which was isolated from Lactococcus latis [52] and is used as a food preservative worldwide [58]. It was 
initially  shown  that  nisin  forms  complexes  with  lipid  I  and  lipid  II,  and  then  inhibits  cell  wall 
biosynthesis [59–61]. Recently, it was shown that nisin can produce short-lived pores that cause the 
cytoplasmic membrane to be permeable [51,60]. Subtilin permeabilizes lipid membranes in a lipid 
II-dependent manner and binds bactoprenyl pyrophosphate [62]. Type-B lantibiotics have been shown to 
inhibit the biosynthesis of cell walls by complexing lipid II, which is essential for the growth and 
replication of bacteria [63]. Mersacidin does not influence the C-terminal D-Ala-D-Ala moiety of the 
lipid intermediate, which induces vancomycin resistance [64]. 
2.3. Alteration of Membrane Potential or Induction of Membrane Permeabilization 
Two major mechanisms of multidrug-resistance are phenotypic alteration of microbes under specific 
growth conditions, such as biofilms, and reduction of drug accumulation into microbes through limited 
uptake or pumping out drugs by multidrug-resistant proteins (MDRPs) [65–68]. Mode of action of 
antimicrobial peptides in the cytoplasmic membrane is considered to be more important than other Int. J. Mol. Sci. 2011, 12                    
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targets. Furthermore, antimicrobial peptides must permeate the cell wall and cytoplasmic membrane to 
reach their intracellular targets, which are nucleic acids and functional proteins [69]. 
Although the exact mechanisms of antimicrobial peptides are not fully understood, they are known to 
cause the efflux of  intracellular  materials  by disrupting the cytoplasmic  membrane via either pore 
formation through a barrel-stave [70] or a toroidal pore [71,72] mechanism,  or through a nonpore 
carpet-like mechanism [73] (Figure 1). In the barrel-stave model (Figure 1A), a variable number of 
channel-forming peptides are positioned in a barrel-like ring around an aqueous pore. Generally, the 
peptide, which is most likely in monomeric form, must associate with the surface of the membrane prior 
to insertion, and the hydrophobic region of the bound peptides is then inserted into the membrane to a 
depth that varies depending on the hydrophobicity of the membrane outer leaflet. When the bound 
peptide reaches a threshold concentration, peptide monomers self-aggregate and are inserted deeper into 
the  hydrophobic  membrane  core.  The  hydrophobic  faces  of  the  peptides  then  align  and  face  the 
hydrophobic lipid core region, whereas their hydrophilic faces form the interior region of a water-filled 
pore [71,74]. This type of transmembrane pore is induced by alamethicin [75] and ceratotoxin [76]. 
Figure  1.  Three typical  modes  of  action  of  antimicrobial  peptides  against  cytoplasmic 
membranes. (A) barrel-stave model; (B) toroidal pore model; (C) carpet model. 
 
In the carpet model (Figure 1C), antimicrobial peptides accumulate on the membrane surface, where 
they  are  electrostatically  bound  to the  anionic  phospholipid  head  groups,  carpeting  the  membrane 
surface at numerous sites. When a threshold peptide concentration is reached, membrane disruption 
occurs  in  a  detergent-like  manner  that  does  not  involve  pore  formation,  and  the  peptides  do  not 
necessarily  insert  into the  hydrophobic  core  [71]. This  model  explains  how  cecropin  P1  [77]  and  
caerin 1.1 [78] disrupt membranes. 
A toroidal pore model (Figure 1B) has been suggested for magainin [79,80], cathelicidin [81,82], and 
HPA3 [83,84]. In this model, antimicrobial peptides bound to the phospholipid headgroup regions of  
the  bilayer  induce  a  high-curvature  fold  in  the bilayer,  enabling  the two  leaflets  of the  bilayer  to Int. J. Mol. Sci. 2011, 12                    
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communicate directly at a torus lined by the leaflets [85]. This differs from the barrel-stave model in that 
antimicrobial peptides are associated onto the lipid head groups even when they are perpendicularly 
inserted into the lipid bilayer [74]. Recently, Han et al. [86] directly observed magainin action on 
artificial vesicles using cryo-transmission electron microscopy (TEM) and an image analysis technique. 
They proposed that magainin-induced pores in lipid vesicles possess a mean diameter of approximately 
8 nm. A pore formed by HPA3 peptide was also observed under TEM in our study [83]. Other groups 
demonstrated that melittin formed a pore via the toroidal mechanism, even though it was dependent on 
the lipid material properties and peptide concentrations [87,88]. 
2.4. Inhibition of Cytoplasmic Proteins Related to Cell Division or Survival 
Although  most  antimicrobial  peptides  primarily  contribute  to  membrane  perturbation,  some 
antimicrobial  peptides  can  penetrate  the  bacterial  cytosol  through  a  flip-flop  mechanism  or  outer 
membrane  protein  forming  channel.  Among  these,  proline-rich  antibacterial  peptides  such  as 
pyrrhocoricin [89], apidaecin [90] and drosocin [91] have been shown to kill bacterial species by binding 
to the multi-helical lid region of the bacterial DnaK heat shock protein, which plays an essential role in 
the initiation of chromosomal DNA replication in an ATP-dependent manner with the other protein, 
DnaJ.  The  C-terminus  of  pyrrhocoricin  was  allowed  to  penetrate  into  cytosol  of  bacteria  and  the 
N-terminus responded to inhibit the ATPase activity of DnaK protein [89]. Microcin B17, which is 
ribosomally synthesized antimicrobial peptides from Enterbacteriaceae, is also believed to inhibit DNA 
replication by targeting DNA gyrase [92].  
2.5. Inhibition of Macromolecular Synthesis through Interaction with Nucleic Acids 
It has been suggested that inhibition of intracellular processes by certain antimicrobial peptides that 
penetrate bacterial cells, such as buforin II [93], PR-39 [94], indolicidin [95], and tPMP [96], may 
contribute to inhibition of the growth of bacterial cells or lead to cell death. Cho et al. [97] found that 
buforin II, a 21-amino acid peptide derived from the Asian toad, Bufo bufo gargarizans, kills bacteria 
through  interaction  with  nucleic  acids  without  membrane  permeabilization,  although  further 
investigation is needed to identify other interactions with as yet unidentified intracellular targets. PR-39, 
which was isolated from the small intestine of the pig, required a lag period of about 8 min to penetrate 
the outer membrane, after which it rapidly killed growing E. coli cells via a mechanism that stops protein 
and DNA synthesis [94]. In the case of indolicidin, although it induced permeabilization of the bacterial 
membrane,  it  did  not  lyse  the  bacterial  cells.  Its  lethal  concentration  allowed  their  filamentous 
morphology  by  inhibition  of  DNA  synthesis  in  E.  coli  cells  [95],  and  it  was  also  found  to  bind 
specifically to DNA rather than RNA [98].  
3. Synergetic Effects between Antimicrobial Peptides and Clinically used Antibiotics 
The combined administration of antibiotics has gained interest because it often results in a synergistic 
antibacterial effect, which enables the dose of the individual drugs to be reduced [99]. In addition, 
certain combination therapies have prevented the development of drug-resistance in bacteria [100,101]. 
A  membranolytic  action  of  antimicrobial  peptide  is  expected  to  produce  synergetic  effects  when 
administered  in  combination  with  conventional  antibiotics,  and  several  studies  have  reported  such Int. J. Mol. Sci. 2011, 12                    
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findings  [27,102,103].  Cirioni  et  al.  [103]  compared the  synergies  of  magainin  II  and  cecropin  A 
administered with or without rifampicin against MDR Pseudomonas aeruginosa strains both in vivo and 
in vitro and found significant reductions in bacterial multiplication, LPS and TNF-α secretion in plasma 
and mortality. This finding suggested that the membrane-permeabilizing activity of peptides allows 
rifampicin to gain access to its  intracellular target. On the other hand, synergistic effects between 
tachyplesin III peptide and imipenem are more effective in vivo mouse model of sepsis than in vitro 
study [104]. Our research also showed that P5 peptide is synergistic in combination with isepamicin 
against antibiotic-resistant P. aeruginosa from patients with cholelithiasis, but not with cefpiramide [105]. 
It suggested that P5 assisted penetration of isepamicin, which is an inhibitor of protein synthesis, into 
isepamicin-resistant  strains  because  P5  exerted  membranolytic  action  against  bacteria.  However, 
cefpiramide, which inhibits bacterial cell wall biosynthesis, was not synergetic. This proposed that 
membrane-acting peptides were effective not β-lactam but aminoglycoside antibiotics in combination 
due to modes of their action.  
4. In Vivo Application of Antimicrobial Peptides 
To data, large numbers of antimicrobial peptides have been  identified  in  nature and designated  
de novo, and many of these have been confirmed to have potent antibacterial activity in vitro. However, 
most of clinical trials have attempted to topical applications, not to systemic applications (parenteral and 
oral). There are several obstacles to the use peptide therapeutic at required sites in the body through 
topical or oral dosing routes. These include the degradation of peptides by intestines, tissues, and serum 
protease and reduced half-life of small peptides through clearance by the kidneys [106]. 
Prior to the increment of circulation half-life, amino acids of antimicrobial peptide must be altered to 
be resistant against proteases or peptidases in serum or tissues. Many naturally isolated peptides have 
cationic amino acids,  lysine and argine, which are easily cleaved by trypsin [107,108]. Moreover, 
chymotrypsin and elastase, which are proteases synthesized by pancreatic acinar cells and secreted in the 
small  intestine  [109],  are  responsible  for  cleaving  peptide  bonds  in  hydrophobic  (phenylalanine, 
tryptophan, and tyrosine) and small amino acids (alanine, glycine, and valine), respectively [110]. To 
overcome  the  proteolytic  cleavage  of  peptides,  several  trials  have  been  conducted  to  evaluate the 
following: substitution of L-amino acids by D-amino acids [111,112], cyclization [113,114], conjugation 
of  fatty  acids  [115],  substitution  by  peptoids  [116,117],  use  of  fluorinated  amino  acids  [118], 
beta-peptide  [119],  and  acylation  [120].  As  novel  candidates,  although  lantibiotics  were  mostly 
employed  in  food  preservation,  type-B  is  another  prospective  candidate  in  biomedical  application 
against infections of MDR bacteria due to its resistance to proteolytic degradation [51]. Specifically, 
mersacidin has been shown to eradicate MRSA colonization in a mouse rhinitis model [121], and its  
in vivo efficacy is better against Streptococcus pyogenes than that of vancomycin [122].  
Another problem involved in the preclinical development of antimicrobial peptides is that they are 
rapidly adsorbed in the kidneys during circulation due to their small size [105]. Several strategies to 
extend the length of the peptides for retardation of excretion through the kidney have been proposed. 
One typical method is attachment of polyethylene glycol (PEG), which is widely used to prolong serum 
half-life [123–125]. However, as with other bioactive peptides, longer PEGylation of antimicrobial 
peptides  is  unfavorable  for  in  vitro  activity,  even  though  it  enhances  the  circulating  lifetime  and 
decreases cytotoxicity [126,127]. Despite this, shorter PEGylation was found to enable retention of the Int. J. Mol. Sci. 2011, 12                    
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in vitro antimicrobial activity of the model peptide and improved activity in the presence of serum in an 
ex vivo assay when compared to unPEGylated peptide [128]. Additionally, proteolytic degradation was 
reduced using this method. Nevertheless, length limitation of PEG and discovery of other methods 
requires further study to enable enhancement of both half-life time and antimicrobial activity in vivo 
prior to clinical trials.  
5. Clinical Development of Antimicrobial Peptides 
Several antimicrobial peptides are being evaluated  in preclinical  and clinical trials with  limited 
applications.  For  example,  Omeganan/MX-226,  which  is  an  indolicidin  analogue,  has  recently 
completed phase III trials the prevention of catheter-related local and bloodstream infection, but was 
dropped for development [129–131]. Additionally, pexiganan/MSI-78 has completed phase III clinical 
trials in the prevention of diabetic foot ulcers [131,132] and plectasin is a fungal defensin peptide that 
exerts bactericidal action against drug-resistant bacteria and is currently in the preclinical phase [132,133]. 
Opebacan, which is a human bactericidal/permeability-increasing protein derivative, has reached the 
phase  II  clinical  trial  for  endotoxemia  in  hematopoetic  stem  cell  transplant  recipients  [131,134]. 
Iseganan/IB-367 from pig protegrin-1 has failed in the prevention of oral mucositis because it did not 
have a comparative advantage to existing therapeutics [132]. Although several antimicrobial peptides 
are progressing to commercial development, records of clinical trials for antimicrobial peptides have 
been restricted to topical applications [132]. 
6. Use of AMPs in Preventing Biofilm 
6.1. Biofilm Formation 
Extended  cultivation  of  bacterial  cells  results  in  adherence  to  animal  tissues  and  inorganic  
materials [135]. This, in turn, allows the formation of a biofilm, which is a multilayered community of 
sessile bacterial cells. Biofilms provide a survival advantage over planktonic or free-floating bacteria by 
enhancing nutrient trapping and colonization [136]. Currently, biofilms are a widespread problem in 
hospitals and healthcare facilities. Indeed, the United States National Institutes of Health found that 80% 
of chronic infections are related to biofilms [4]. Moreover, many studies have found that biofilms are 
associated with dental plaque [137,138], endocarditis [139], lung infection [140,141], and infection 
through medical devices [142]. 
Biofilm-formation  by  bacteria  is  achieved  via  responses  to  various  factors,  such  as  nutritional  
cues, cellular recognition of attachment sites on the surface, exposure to sublethal concentrations of 
antibiotics, and environment stresses [143,144]. As shown in Figure 2, biofilm-formation is generally 
initiated  by  the  attachment  of  planktonic  cells  to  a  surface  through  weak  van  der  Waals  forces  
(Figure 2(1)), and the colonists are anchored tightly or irreversibly by pili (Figure 2(2)). To facilitate the 
arrival and attachment of other planktonic cells, the initial cells construct various adhesion sites and the 
matrix (Figure 2(3)). Bacterial cells are then embedded within this matrix of extracelluar polymeric 
substance (EPS), which is composed of extracelluar DNA, proteins, lipids, and polysaccharides with 
various  configurations  [145].  These  components  are  very  important  targets  for  overcoming  both 
biofilms and drug-resistant bacteria [146]. During colonization, some bacteria can communicate through Int. J. Mol. Sci. 2011, 12                    
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a quorum sensing (QS) system [147,148] via small molecules called autoinducers and controls collective 
behaviors, such as bioluminescence, virulence factor production, and biofilm formation [149–151]. 
Autoinducers  in  Gram-negative  and  -positive  bacteria  were  known  to  acyl-homoserine  lactone 
molecules and oligopeptides, respectively. It is currently considered a good target for preventing biofilm 
infection. Subsequently,  the grown or developed biofilm provides  increased antibiotic-resistance to 
bacterial colonies through cell division and recruitment (Figure 2(4)). Later, the developed biofilms are 
dispersed  and  the  bacteria  move  to  other  surfaces,  such  as  organs,  tissues,  and  medical  devices  
(Figure 2(5)), where the biofilm formation process occurs again.  
Figure 2. General overview of bacterial biofilm development. (1) reversible adsorption of 
bacteria; (2) irreversible attachment of bacteria; (3) production of extracelluar polymeric 
substance and biofilm growth; (4) maturation; (5) dispersion. After dispersion of the biofilm, 
bacteria  move  to  other  organs,  tissues,  or  surfaces  and  a  new  biofilm  is  formed  via  
stages (1)–(5). 
 
6.2. Applications to Prevent or Remove Biofilms 
Two main concepts in the prevention of biofilms are dispersion of the biofilm EPS and eradication of 
the  bacteria  embedded  in  the  EPS. Typically,  lethal  or  inhibiting  concentrations  of  antibiotics  are 
significantly increased by up to 1000-fold against biofilm bacteria because they are unable to translocate 
into EPS and therefore do not reach the bacterial cells. In contrast, antimicrobial peptides are believed to 
have the potential  for use as anti-biofilm agents due to their different mechanisms, which  include 
membrane-disrupting action, functional inhibition of proteins, binding with DNA, and detoxification of 
polysaccharides (lipopolysaccharide and lipoteichoic acid). The EPSs of biofilms contain considerable 
amounts of polysaccharides, proteins, nucleic acids and lipids [152]. For example, certain antimicrobial 
peptides can be transferred in biofilm EPS through holes or pores formed in the lipid component of the 
EPS, while others can disperse biofilms. 
6.2.1. In Vitro Anti-Biofilm Activity of Antimicrobial Peptides against Biofilm of MDR Bacteria 
Pseudomonas  aeruginosa  is  the  significant  pulmonary  pathogen  affecting  patients  with  cystic  
fibrosis [153], and this organism forms a biofilm on medical devices and tissues. LL-37, a human 
cationic host defense peptide, showed a potent inhibitory activity in biofilm formation at a concentration Int. J. Mol. Sci. 2011, 12                    
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of  0.5  µg/mL  against  P.  aeruginosa  biofilm  and  reduced  pre-grown  biofilms  [154].  It  was  also 
demonstrated that these effects were achieved by decreasing the attachment of bacterial cells onto the 
surface, stimulating twitching motility mediated by type IV pili, and down-regulating the genes related 
to the QS system [154]. LL-37 also inhibited both the attachment action and development of biofilms by 
Staphylococcus epidermidis, being commensal in human skin and mucous membrane [155]. Moreover, 
LL-37 potently  inhibited the growth of planktonic cells  and biofilm  formation against Francisella 
novicida, which causes the disease tularemia [156]. Dashper et al. reported that kappacin, nonglycosylated 
κ-casein (109-169), showed a significant reduction of Streptococcus mutans biofilm in the presence  
of  ZnCl2.  In  addition,  systematic  replacement  of  an  N-terminal  amino  acid  with  fatty  acids  [157]  
or  conjugation  of  fatty  acids  in  N-terminus  of  synthetic  short  peptide  [158]  leads  to  enhanced  
antibiofilm activity. 
6.2.2. Anti-Biofilm Activity in Medical Devices 
Recently, the beneficial effects on the survival and quality of life of patients have led to increased use 
of  medical  implants  [159].  However,  medical  device-related  infections  are  often  serious  because 
contaminating bacteria on the surface of these devices can form biofilms with dense layers that are very 
difficult to completely remove. Currently available antibiotics fail to eradicate such infections because 
they are inactive in the presence of biofilms or MDR bacteria [160]. Therefore, many researchers are 
suggesting that antimicrobial peptide administered alone or in combination with other molecules may be 
able to solve this problem. 
Yoshinari et al. investigated that the adsorption of conjugated lactoferricin onto titanium surface  
was  enhanced  in  the  presence  of  hexapeptidic  titanium-binding  peptide  and  the  attachment  of 
Porphyromonas  gingivalis  was  decreased  onto  this  peptide-modified  specimen,  indicating  that 
surface-modification with peptides can be presented as preventing method for biofilm formation on 
medical  devices  [161].  Melimine,  which  is  a  non-hemolytic  hybrid  peptide  between  melittin  and 
protamine, did not induce resistance against S. aureus or P. aeruginosa during repeated passage in 
sub-minimal inhibitory concentrations, and reduced bacterial adhesion to contact lenses to which it was 
covalently  linked  [162].  Furthermore,  silicone  hydrogel  lenses  with  melamine  reduced  contact 
lens-induced acute red eye in the P. aeruginosa guinea pig model and prevented contact lens induced 
peripheral ulcers in a S. aureus rabbit model [163]. Citropin 1.1, isolated from the green tree frog Litoria 
citropa, has potent anti-biofilm activity and showed enhanced activity against S. aureus biofilm when 
administered in combination with rifampin and minocycline [164]. The treatment of central venous 
catheters pre-treatedwith citropin 1.1 peptides and/or antibiotics significantly reduced bacterial counts of 
biofilm in a S. aureus infection rat model [160]. 
6.2.3. Anti-Biofilm Activity against Oral Plaque 
Dental plaque is a complex biofilm community that forms on the teeth and oral tissues of shedding 
and retentive surfaces [165,166]. Dental plaque develops under a variety of conditions and environments, 
and  is  composed  of  different  bacterial  species  [167,168].  Oral  biofilms  cause  dental  cavities  and 
periodontal  diseases,  such  as  gingivitis  and  chronic  periodontitis  [169,170].  Various  therapeutic Int. J. Mol. Sci. 2011, 12                    
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approaches have been investigated to prevent or remove oral biofilm, here we introduce the applications 
of antimicrobial peptides. 
Gingival epithelial cells express antimicrobial peptides such as human beta-defensin-2 (hBD-2), 
psoriasin (S100A7), and ribonuclease 7 (RNase 7), which play important roles in innate immunity, 
through biofilm stimulation [171]. Expression of these peptides can be genetically regulated on epithelial 
cells.  Another  study  showed  that  combined  treatment  with  chlorhexidine  and  bacteriocin  PsVP-10 
synergistically  reduced  the  number  of  the  biofilm-forming  bacteria,  Streptococcus  mutans  [172]. 
Lactoferrin (LF) which exists in saliva and gingival crevicular fluids is related to host defense against 
oral pathogens [173]. The initial attachments of Streptococcus gordonii and S. mutans forming biofilm in 
oral cavity were inhibited in the presence of LF [174]. It was recently investigated that LF was able to 
inhibit planktonic growth of Porphyromonas gingivalis and Prevotella intermedia, which make biofilm 
in the subgingival plaque, and to suppress biofilm formation at a low concentration (≥8 µg/mL) [173]. 
LF alone or in combination with antibiotics also showed a reduction of pre-forming biofilm [173]. 
Moreover,  in  small-scale  clinical  trial,  patients  administered  a tablet  with  0.3  g of  bovine  LF  for  
3 months had an effect on reduction of bacterial numbers in the subgingival plaque [175]. Leung et al. 
proposed an interesting approach in which a chewing gum containing both KSL-W synthetic peptide and 
cetylpyridinium chloride displayed a dose-dependent reduction against a biofilm of human salivary 
bacteria [170]. Gum formulation with this combination was proposed to be used as an antiplaque agent 
or adjunct for oral hygiene.  
6.2.4. Others 
Another approach to inhibiting biofilm formation is the use enzymes that can degrade the EPS of 
biofilm and detach established biofilm colonies. Moreover, biofilm-dispersing enzymes administered in 
combination treatment with antimicrobial agents will allow them to kill bacteria embedded in EPS [176]. 
Kaplan et al. suggested that deoxyribonuclease I and glycoside hydrolase dispersin B are useful as 
anti-biofilm agents due to the dispersing action of EPS layers on medical devices [177,178]. In addition, 
therapeutic treatment of combination treatments with antimicrobial peptides may result in significant 
synergetic-effects against MDR bacteria and the formation of biofilms.  
8. Conclusions 
Antimicrobial peptides can be the next generation of antibiotics for combating multi-drug resistant 
and/or biofilm forming bacterial infections. These peptides have a strong potential for application as 
nanofilms or other coating materials for surgical devices, including catheters. Even though there are 
drawbacks to the use of peptides as therapeutics, such  as  low  bioavailability and  high cost, these 
obstacles may be overcome since a great deal of effort is being conducted to circumvent the problems 
associated  with  various  methods  including  the  use  of  D-  or  unnatural  amino  acid,  formulation, 
recombinant DNA expression of peptides, addition of fatty acyl chains to short peptides. Therefore, it is 
expected that antimicrobial peptides will become the drugs of choice for emerging bacterial infections in 
the future.  Int. J. Mol. Sci. 2011, 12                    
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